

REMARKS

Amendments to the Specification

Applicants have amended the title as set forth hereinabove. The amended title is descriptive of the type of compounds claimed herein.

Amendments To The Claims

The claims have been amended in accord with the restriction requirement which is discussed below. Claims 13 and 15 have been canceled by this amendment. In claim 1 the term "represents" has been replaced with the term "is". In claims 2-5 and 9-10 the term "A" was replaced by "The" and in claims 2-5 the phrase "or a pharmaceutically acceptable salt thereof" was added. In claims 1, 6 and 14 the term "derivative" was replaced by the term "salt". In claims 1, 5 and 6 the term "link" was replaced by the term "bond." Support for these amendments is in the specification as originally filed, including the original claims.

Claim 1 was amended by restricting the definition of ring A to a piperidine and by limiting W and X to N and NR, respectively. In addition, certain instances of the term "one or more" has been replaced by the phrase "one to three" and the term "link" replaced by the term "bond". Support for this amendment is in the specification as originally filed and in original claim 1.

Claim 3 was amended by limiting the definition of Y to chloro and Y' to hydrogen. Claim 4 was amended by limiting the definition of R¹ to the specified groups. Claim 6 was amended into independent form. Claim 7 was amended into a compound claim. Method of treatment claims 8-12 were amended by limiting the disorders treated as set forth in those claims. Support for these amendments is in the specification as originally filed, including the detailed description section and the original claims.

Claim 14 was amended by replacing the phrase "formulation including" with "composition comprising". Support for this amendment is in the specification as originally filed, including original claim 14.

Claim 15 was amended by replacing the term "formulation" with "composition" and by replacing "derivative" with "salt." Support for this amendment is in the specification as originally filed, including original claim 15.

No new matter has been added by these amendments. Applicants reserve the right to file continuation or divisional applications directed to canceled or deleted subject matter.

The Restriction Requirement Under 35 U.S.C. § 121

Claims 1-15 are currently pending in this application. The Examiner has required restriction of the invention into one of three groups: Group I, claims 1, 3-5 and 7-15, drawn to compounds of Formula I wherein ring A is a piperidine, W is N and X is O and methods of using the same; Group II,

claims 1, 3-15, drawn to compounds of Formula I wherein ring A is a piperidine, W is N and X is NR and methods of using the same; and Group III, claims 1-5 and 7-15, drawn to compounds outside of Groups I-II and methods of using the same. The Examiner also required the election of a single species.

Applicants hereby elect Group II, compounds of Formula I in which ring A is a piperidine, W is N and X is NR and methods of using the same. The Examiner has also requested the election of a single species. Applicants hereby elect the species [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-3-yl)-methanone or a pharmaceutically acceptable salt thereof, which is the compound of Example 1 and is claimed in claim 6 (first species) and in claim 7. The elected species reads on claims 1-12 and 14, as amended.

Entry of the foregoing amendments to the claims and reconsideration in view of the foregoing remarks is respectfully requested. An early and favorable response is respectfully solicited.

Respectfully submitted,

Date: 16 September 2008
Pfizer Inc.
Patent Department
Eastern Point Road, MS 8260-1611
Groton, Connecticut 06340
(860) 715-6645

/ John A. Wichtowski /
John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032